Can patients with astigmatism and EOR safely use Mounjaro (tirzepatide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Astigmatism and "EOR" Are Not Contraindications to Mounjaro

Astigmatism is not a contraindication to Mounjaro (tirzepatide), and there is no established medical condition abbreviated as "EOR" that would preclude its use. The term "EOR" does not correspond to any recognized ophthalmologic or medical diagnosis in standard clinical practice.

Actual Ophthalmologic Contraindications and Concerns

According to the FDA drug label, Mounjaro is contraindicated only in patients with:

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to tirzepatide 1

Retinopathy Considerations (Not Astigmatism)

The confusion may stem from concerns about diabetic retinopathy, which is a different condition entirely from astigmatism:

Patients excluded from tirzepatide trials included those with uncontrolled/unstable diabetic retinopathy or maculopathy 2. This is a precautionary measure, not an absolute contraindication in clinical practice.

Recent evidence actually suggests tirzepatide may reduce diabetic retinopathy risk:

  • A 2026 multicenter US cohort study found tirzepatide associated with reduced 12-month risk of incident proliferative diabetic retinopathy (RR 0.705), DR with macular edema (RR 0.624), and need for intravitreal anti-VEGF injection (RR 0.479) 3

Optic Nerve Concerns (Emerging Data)

There is emerging concern about non-arteritic anterior ischemic optic neuropathy (NAION) with GLP-1 receptor agonists:

  • A 2025 population-based study found increased risk of NAION with semaglutide or tirzepatide (HR 1.76,95% CI 1.01-3.07), though absolute risk remained very low (0.04% vs 0.02%) 4
  • Individual case reports exist of NAION following tirzepatide 5
  • However, the North American Neuro-Ophthalmology Society and American Academy of Ophthalmology do not recommend routinely discontinuing these medications, emphasizing shared decision-making rather than blanket contraindications 6

Clinical Approach

For patients with simple astigmatism: Proceed with Mounjaro without concern—astigmatism is a refractive error unrelated to medication safety.

For patients with diabetic retinopathy:

  • Uncontrolled/unstable retinopathy warrants caution and ophthalmology consultation before initiating tirzepatide 2
  • Stable retinopathy is not a contraindication; emerging data suggests potential benefit 3
  • Close monitoring during dose escalation is prudent

For patients with prior NAION or high-risk optic nerve disease:

  • Engage in shared decision-making weighing metabolic benefits against uncertain optic nerve risks 6
  • Consider ophthalmology consultation before initiation
  • Counsel patients to report sudden vision loss immediately

Dosing remains standard: Start 2.5 mg subcutaneously weekly, escalate by 2.5 mg every 4 weeks to maximum 15 mg (adults) or 10 mg (pediatrics) 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.